Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2021 Dec 14;21(2):336–346. doi: 10.1158/1535-7163.MCT-21-0395

Figure 2. ROS1F2004C induces resistance to entrectinib.

Figure 2.

A & B, Immunoblot analysis of the phosphorylated and total proteins shown from Ba/F3 CD74-ROS1F2004C (A) and Ba/F3 EZR-ROS1F2004C (B) lysates treated with the indicated inhibitors for 4 hours. Vehicle indicates DMSO treatment.